A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant

Haematologica. 2024 Jun 1;109(6):1994-1999. doi: 10.3324/haematol.2023.284544.

¹ Department of Hematology and Hematopoietic Cell Transplantation.
² Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA.
³ Fred Hutchinson Cancer Center, Seattle, WA.
⁴ Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.
⁵ Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
⁶ Department of Shared Resources-Clinical Trial Office.
⁷ Department of Clinical Research, City of Hope National Medical Center, Duarte, CA.
⁸ University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO.
⁹ Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.
¹⁰ Department of Hematology and Hematopoietic Cell Transplantation. ddiamond@coh.org.

No abstract available

Publication types